1. Home
  2. BFH vs EWTX Comparison

BFH vs EWTX Comparison

Compare BFH & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bread Financial Holdings Inc.

BFH

Bread Financial Holdings Inc.

N/A

Current Price

$76.11

Market Cap

3.0B

ML Signal

N/A

Logo Edgewise Therapeutics Inc.

EWTX

Edgewise Therapeutics Inc.

N/A

Current Price

$22.39

Market Cap

2.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BFH
EWTX
Founded
1996
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.0B
2.5B
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
BFH
EWTX
Price
$76.11
$22.39
Analyst Decision
Hold
Buy
Analyst Count
16
9
Target Price
$65.29
$35.89
AVG Volume (30 Days)
787.8K
1.2M
Earning Date
01-29-2026
11-06-2025
Dividend Yield
1.21%
N/A
EPS Growth
55.00
N/A
EPS
9.68
N/A
Revenue
$2,509,000,000.00
N/A
Revenue This Year
$59.03
N/A
Revenue Next Year
$3.92
N/A
P/E Ratio
$7.83
N/A
Revenue Growth
1.70
N/A
52 Week Low
$38.21
$10.60
52 Week High
$76.66
$35.50

Technical Indicators

Market Signals
Indicator
BFH
EWTX
Relative Strength Index (RSI) 80.94 50.26
Support Level $73.82 $22.77
Resistance Level $76.66 $25.00
Average True Range (ATR) 1.83 1.32
MACD 0.38 -0.40
Stochastic Oscillator 92.45 2.49

Price Performance

Historical Comparison
BFH
EWTX

About BFH Bread Financial Holdings Inc.

Formed by a combination of JCPenney's credit card processing unit and The Limited's credit card bank business, Bread Financial is a provider of private-label and co-branded credit cards, loyalty programs, and marketing services. The company's most financially significant unit is its credit card business that partners with retailers to jointly market Bread's credit cards to their customers. The company also retains a minority interest in spun-off LoyaltyOne, which operates the largest airline miles loyalty program in Canada and offers marketing services to grocery chains in Europe and Asia.

About EWTX Edgewise Therapeutics Inc.

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.

Share on Social Networks: